Glycogen synthase kinase 3b (GSK-3b) is a pivotal signaling node that regulates a myriad of cellular functions and is deregulated in many pathological conditions, making it an attractive therapeutic target. Inhibitory Ser-9 phosphorylation of GSK3b by AKT is an important mechanism for negative regulation of GSK3b activity upon insulin stimulation. Here, we report that Thr-7 and Thr-8 residues located in the AKT/PKB substrate consensus sequence on GSK3b are essential for insulin-stimulated Ser-9 phosphorylation in vivo and for GSK3b inactivation. Intestinal cell kinase (ICK) phosphorylates GSK3b Thr-7 in vitro and in vivo. Thr-8 phosphorylation partially inhibits GSK3b, but Thr-7 phosphorylation promotes GSK3b activity and blocks phospho-Ser-9-dependent GSK3b autoinhibition. Our findings uncover novel mechanistic and signaling inputs involved in the autoinhibition of GSK3b.
Glycogen synthase kinase 3b (GSK3b) is a multi-functional protein kinase that plays an important role in amazingly diverse intracellular signaling actions by targeting a broad range of substrates, including metabolic enzymes, transcriptional factors, and structural and signaling proteins [1, 2] . Major mechanisms that regulate GSK3b activity include phosphorylation, protein complex formation, and intracellular localization [1] [2] [3] . Phosphorylation of GSK3b at serine 9 [4] and tyrosine 216 [5] is the most widely studied mechanism of 'YinYang' regulation. Under basal/resting conditions, GSK3b is constitutively active in cells. Tyr-216 phosphorylation at the activation loop is critical for GSK3b activity by inducing a conformational change that allows substrates to bind GSK3b [6] . Either the autokinase activity [7, 8] or a distinct tyrosine kinase [9, 10] was reported to account for Tyr-216 phosphorylation. Growth factors induce phosphorylation of GSK3b at Ser-9, which triggers an autoinhibitory effect on GSK3b activity. Several members of the AGC (protein kinase A/G/C) family of protein kinases, including Akt [11] [12] [13] , p90Rsk [4, [14] [15] [16] , p70 S6K [4, 17] , PKA [18, 19] , and certain isoforms of PKC [20, 21] , have been found to phosphorylate GSK3b Ser-9 under diverse upstream stimuli and conditions. Although GSK3b does not have a strict substrate consensus motif, it is one of a few unique protein kinases that strongly prefer prior phosphorylation of their substrates by a priming kinase at a proximal serine/threonine C-terminal to the target residue [22] . Structural analysis has revealed that GSK3b relies on a phosphorylated serine or threonine residue at the P + 4 position in the substrate for the alignment of its b-and a-helical domains into a catalytically active conformation [23] [24] [25] . A recent crystal structure of GSK3 bound to its phosphorylated N-terminus showed that the pS9 auto-inhibitory peptide binds to GSK3 as a pseudo-substrate by occupying the primed Abbreviations AKT/PKB, protein kinase B; GSK3, glycogen synthase kinase 3; ICK, intestinal cell kinase; KD, kinase dead; WT, wild-type.
substrate binding pocket and stabilizes a catalytically competent conformation [26] . In the inhibitory peptide-binding pocket, the phosphate of phosphorylated Ser-9 in the primed P + 4 position forms hydrogen bonds with Arg-96, Arg-180 and Lys-205, and Thr-7 at the P + 2 position packs against Phe-67 [26] . Mutation of Phe-67 to alanine severely impairs GSK3b catalytic activity, suggesting that the interaction between Phe-67 and Thr-7 is important for stabilizing a catalytically active conformation [26] . Highly conserved Thr-7 and Thr-8 residues are adjacent to Ser-9 within the AKT/PKB substrate consensus sequence R-P-R-T7-T8-S9-F on the N-terminus of GSK3b. Although Thr-7 and Thr-8 are not stringently required for AKT substrate specificity, they are positioned in the AKTGSK3b binding interface for potential contacts with residues (e.g. Glu-279) in the AKT activation segment [27] . These structural information together raised the question as to whether Thr-7 and Thr-8 play any significant role in AKT phosphorylation of Ser-9 and GSK3b autoinhibition.
Materials and methods

Reagents and plasmids
Human insulin was from Lilly USA (Indianapolis, IN, USA). Calyculin A was from Calbiochem (distributed through MilliporeSigma, Burlington, MA, USA). All synthetic polypeptides were from ABI Scientific (Sterling, VA, USA). The MISSION TRC ICK shRNA Target Set and the control nontargeting shRNA vector were obtained from Sigma (St. Louis, MO, USA), as described in [28] . GST-ICK WT (wild-type) and K33M (kinase dead) in pEBG-GST were described previously in [29, 30] . HA-GSK3b WT, S9A, and K85A in pCDNA3 (Addgene plasmids #14753, #14754, and #14755) were gifts from Dr. Jim Woodgett [14] through Addgene (Cambridge, MA, USA). HAGSK3b T7A and T8A mutants were generated using the QuikChange Site-Directed Mutagenesis Kit from Stratagene (San Diego, CA, USA) and confirmed by DNA sequencing at DNA Sciences Core, University of Virginia.
Cell Lines, transfection, and infection
HEK293T and RIE-Ras 12V (gift from Dr. John Barnard,
The Ohio State University) cells were maintained at 37°C and 5% CO 2 in DMEM supplemented with 10% FBS. RIE-1 rat intestinal epithelial cells were obtained from Ken Brown (Cambridge, UK). RIE-Ras 12V cells were established by stable transfection of the parental RIE cells with pSV2-H-Ras(12V) containing human sequences encoding the constitutively active H-Ras(12V) protein, as described in [31] . HEK293T cells were transfected using either a calcium phosphate protocol as described in [30, 32] or the lipofectamine 2000 reagent following the manufacturer's instruction (Invitrogen, Carlsbad, CA, USA). Lentiviral shRNA particles were generated in HEK293T cells as described in [28, 33] and used to infect RIE-Ras 12V cells for RNA interference.
Antibodies, western blot, and peptide competition assay
The polyclonal GSK3b phospho-Thr-7 antibody was generated in rabbits against keyhole limpet hemocyanin-coupled phospho-GSK3b peptide RPR[pT 7 ]TSFAES (aa 4-13) at GenScript (Piscataway, NJ, USA). Phosphopeptide-specific antibodies were affinity-purified through a positive selection over phosphopeptide antigens followed by negative selections over nonphosphopeptide antigens and phospho-T7-deficient GSK3b-T7A protein antigens. ICK antibody was described in [28] . All commercial antibodies for signaling pathways were from Cell Signaling Technology, Inc. (Danvers, MA, USA). Methods for preparation of cell extracts and western blotting were detailed in [33, 34] . Blocking peptide competition assay was used to validate the specific reactivity of phosphosite-specific antibodies (Fig. S1 ). Primary antibodies (1-2 lgÁmL À1 ) were preincubated with blocking peptides (200-fold molar excess) at 4°C for 16-18 h. The antibody-peptide mixture was cleared of any insoluble proteins by centrifugation at 15K rpm for 15 min prior to the use of preincubated antibodies for western blot.
In vitro kinase assay
To assess GSK3b Thr-7 phosphorylation by ICK and GSK3b Ser-9 phosphorylation by AKT, HA-GSK3b kinase-dead (KD) proteins were expressed in HEK293T cells, affinity-purified from cell extracts by anti-HA agarose beads. HA-GSK3b substrates (0.5-1 lg) were then incubated with active His-ICK 1-291 [28, 32] or His-Akt1/PKBa (Millipore, Dundee, UK) proteins (50-100 ng) and 100 lM [c-
32
P]-ATP (PerkinElmer, Waltham, MA, USA) in kinase buffer [50 mM HEPES (pH 7.5), 10 mM MgCl 2 , 2 mM DTT, and complete protease and phosphatase inhibitor cocktails (Roche, Basel, Switzerland)] at 30°C for 20 min. After the reaction was terminated by addition of 2X SDS sample buffer, the reaction samples were processed and analyzed for radioactivity by autoradiograph as described in [28, 32] . For nonradioactive assay, the above reaction mixtures were incubated with unlabeled ATP and the reactivity of GSK3b against phospho-T7 and phospho-S9 antibodies was analyzed by western blot.
To measure GSK3b activity against primed substrates, HA-GSK3b (WT, T7A, T8A, and S9A) proteins were expressed in HEK293T cells. After insulin (100 nM) stimulation for 60 min, recombinant GSK3b proteins were affinity-purified and then incubated with 60 lM PhosphoGlycogen Synthase Peptide-2 (p-GSP2) (Millipore, Burlington, MA, USA) [4] and 100 lM [c- 32 P]-ATP (PerkinElmer, Waltham, MA, USA) in kinase buffer at 30°C for 20 min. The reaction mixtures were spotted onto phosphocellulose paper (p81, Whatman), washed in 0.75% phosphoric acid, rinsed in acetone, and counted for radioactivity in a liquid scintillation counter.
Peptide inhibition assay
Peptides were prepared by solid-phase synthesis, HPLC purified, and verified for composition and purity (>95%) by mass-spectrometry (ABI Scientific Inc., Sterling, VA, USA). Peptides were derived from the N-terminal residues 3-12 of GSK3b [24] 
, and nonphospho-control [GRPRTTSFAE] . Phospho-glycogen synthase peptide-2 (p-GSP2) (Millipore, Burlington, MA, USA) was used as the prime-phosphorylated substrate for GSK3b [4] . Purified recombinant GSK3b (BioLabs, Ipswich, MA, USA), 60 lM p-GSP2 substrates, and 1 mM GSK3b N-terminal peptides in kinase buffer supplemented with complete protease and phosphatase inhibitors (Roche) and 100 lM [c-
32 P]-ATP (PerkinElmer) were incubated at 30°C for 20 min. The reaction mixtures were assessed for radioactivity on phosphocellulose paper as described above.
Statistical analysis
Quantified experimental data were analyzed by the Student t-test. Data were reported as mean AE standard deviation (SD). P-values less than 0.05 were considered as significant.
Results
Highly conserved Thr-7 and Thr-8 residues are essential for insulin-stimulated Ser-9 phosphorylation in vivo and autoinhibition of GSK3b
Peptide and protein library screening has defined the substrate specificity for AKT/PKB as RXRXXS/TΦ, with strong preference for arginine residues at both -3 and -5 positions and hydrophobic amino acids (Φ) in the +1 position [35] . The structure of AKT/PKB in complex with a GSK3b peptide containing residues 3-12 of GSK3b provided the structural basis for this substrate selectivity [27] . In the N-terminal segment of GSK3b, like Ser-9 both Thr-7 and Thr-8 are highly conserved across different species (Fig. 1A ). Thr-8 at the -1 position is solvent exposed; Thr-7 at the -2 position forms a hydrogen bond with Glu-279 in the activation segment of AKT [27] . Despite these insights from biochemical and structural analyses of the Nterminal peptide of GSK3b, it remains to be determined whether Thr-7 and Thr-8 play an important role in the full-length GSK3b when it interacts with AKT in response to insulin.
To examine the role of Thr-7 and Thr-8 in AKT phosphorylation of Ser-9, we conducted both in vitro and in vivo assays for Ser-9 phosphorylation on HAtagged GSK3b proteins containing the T7A or T8A point mutation. In vitro, alanine mutations replacing either Thr-7 or Thr-8 did not prevent Ser-9 phosphorylation of HA-GSK3b proteins by AKT (Fig. 1B) . Compared with wild-type HA-GSK3b, AKT phosphorylates HA-GSK3b containing the T7A mutation equally well, but phosphorylates HA-GSK3b containing the T8A mutation to a lesser extent (Fig. 1B) . In contrast, mutating either Thr-7 or Thr-8 to alanine significantly attenuated Ser-9 phosphorylation of HAGSK3b in cells at the basal level ( Fig. 1C ) and during starvation followed by insulin stimulation (Fig. 1E ). Impaired Ser-9 phosphorylation on HA-GSK3b (T7A) mutant proteins did not correlate with a significant reduction in the amount of AKT associated with HAGSK3b (T7A), suggesting that Thr-7 mutation does not significantly alter the binding affinity between AKT and GSK3b (Fig. 1D) . Using a peptide competition assay, we showed that p-Ser9 recognition was displaced to a comparable extent by the blocking polypeptide containing p-Ser9 and by the same polypeptide containing Thr7 mutated to Ala (Fig. S1 ). This observation eliminated the concern that an adjacent mutation has any significant impact on epitope recognition by the phospho-Ser9-specific antibody used in Fig. 1 .
We then assessed the effects of T7A and T8A mutations on GSK3b activity upon insulin stimulation. HA-tagged GSK3b wild-type (WT) and mutant proteins purified from insulin-stimulated HEK293T cells were assessed for phosphotransferase activity against prime phosphorylated glycogen synthase (p-GS) peptide substrates. HA-GSK3b WT proteins purified from unstimulated HEK293T cells served as the baseline control. Consistent with prior studies, HA-GSK3b WT proteins containing elevated p-S9 signals after insulin stimulation exhibited a significant reduction in GSK3b activity. This inhibitory effect on GSK3b was abolished by not only the S9A mutation but also the T7A or the T8A mutation (Fig. 1F) . We concluded from these results that conserved Thr-7 and Thr-8 residues are essential for insulin-stimulated Ser-9 phosphorylation in vivo and autoinhibitory effect on GSK3b activity toward its primed substrates.
The effect of T7A or T8A mutation on GSK3b Ser-9 phosphorylation cannot be abolished by inhibition of PPP family phosphatases T7A or T8A mutation resulted in a decrease in Ser-9 phosphorylation of GSK3b in cells (Fig. 1) . A significant question was whether dephosphorylation of p-Ser-9 was enhanced when Thr-7 or Thr-8 was mutated to Ala. To test this possibility, after insulin stimulation we treated cells with Calyculin A, a potent, cell permeable inhibitor of PPP (phosphoprotein phosphatases) family including PP1, PP2A, PP4, PP5, PP6. 
AKT substrate consensus moƟf: R-X-R-X-X-S/T , T8A) proteins were expressed in HEK293T cells. After overnight starvation in 0.1% low-serum medium, cells were treated with 100 nM insulin for various time ponits as indicated. Phospho-S9 specific and total GSK3b signals in whole cell extracts (WCE) or in anti-HA immunoprecipitates were analyzed by western blot. Shown are representative data from three independent experiments. (F) HA-GSK3b WT and mutant (T7A, T8A, S9A) proteins were expressed in HEK293T cells. After starvation and insulin stimulation (100 nM, 60 min), cells were lysed and HA-GSK3b proteins were affinity-purified on anti-HA agarose beads. HA-GSK3b WT proteins purified from unstimulated cells served as the control. In vitro kinase assay was conducted to assess GSK3b activity toward p-GS peptide substrates. Shown are GSK3b activities relative to the control, mean AE SD, n = 3 independent experiments, *P < 0.01.
As expected, Calyculin A treatment markedly enhanced insulin-induced phosphorylation of mTOR, S6K, GSK3, and ERK ( Fig. 2A) . Inhibition of phosphatase activities was not sufficient to prevent decreased phosphorylation of Ser-9 on GSK3b caused by T7A or T8A mutation (Fig. 2B) . This result suggests that phosphatase actions are not the main driver of the effect of the alanine substitution for Thr-7 or Thr-8 on Ser-9 phosphorylation of GSK3b.
ICK can specifically phosphorylate GSK3b Thr-7 in vitro and in vivo Thr-7 in the N-terminus of GSK3b fits in the substrate consensus motif R-P-X-[S/T]-P/A/S/T for intestinal cell kinase (ICK) as determined in [32] . Thr-7 residue and the ICK substrate consensus sequence R-P-R-T7-T found in human GSK3b are well conserved across different species (Fig. 1A) . ICK is a ubiquitously expressed serine/threonine protein kinase in the CMGC (CDK/ MAPK/GSK3/CLK) group of the human kinome [29, 30] . We therefore tested whether ICK is an upstream kinase for GSK3b-T7. GSK3b phospho-T7 and phospho-S9 antibodies were utilized to monitor specific phosphorylation of GSK3b Thr-7 and Ser-9 by western blot. The phosphosite specificity of these two antibodies was validated by a peptide competition assay (Fig. S1 ). Synthetic peptides containing p-S9 or p-T7 specifically competed with antibodies recognizing p-S9 or p-T7, respectively (Fig. S1 A, D) . Furthermore, phosphorylation of adjacent sites did not seem to significantly perturb recognition by GSK-3b phosphosite-specific antibodies (Fig. S1 ). The phospho-peptide with both p-T7 and p-S9 sites appeared to compete with each phosphosite-specific antibody to p-S9 or p-T7 equally well in comparison to polypeptides containing only one site phosphorylated (Fig. S1 B, D) . Using HA-tagged catalytically inactive GSK3b proteins as the substrate, we showed that purified His-AKT and His-ICK proteins [28, 32] can phosphorylate GSK3b in vitro (Fig. 3A) . By western blot, we further showed the strong reactivity of HA-GSK3b to HA-GSK3β-pS9 Short Exposure Fig. 2 . The inhibitory effect of the T7A or T8A mutation on GSK3b Ser-9 phosphorylation cannot be abolished by inhibition of phosphatase activities. (A) HEK293T cells were starved in low-serum medium overnight, and then treated with 100 nM insulin for 30 min followed by 50 nM Calyculin A for 30 min prior to lysis. Whole cell extracts were blotted for both total and phosphorylation signals of mTOR, S6K, GSK3, and ERK.
(B) HA-GSK3b WT or mutant (T7A, T8A) proteins were expressed in HEK293T cells. After overnight starvation in 0.1% low-serum medium, cells were treated with 100 nM insulin for 30 min followed by 50 nM Calyculin A for 30 min prior to lysis. HA-GSK3b proteins were isolated from whole cell lysate by anti-HA immunoprecipitation. Phospho-S9 and total GSK3b signals in anti-HA immunoprecipitates were analyzed by western blot. Note that Calyculin A is a potent, cell permeable inhibitor of PPP family phosphatases including PP1, PP2A, PP4, PP5, and PP6.
phospho-S9 and phospho-T7 specific antibodies after co-incubating HA-GSK3b with His-AKT and His-ICK 1-291 respectively in vitro (Fig. 3B ). This result confirmed the phosphosite specificity of AKT on Ser-9 and ICK on Thr-7. We further validated the specificity of ICK on GSK3b Thr-7 by showing that only T7A, but not T8A or S9A mutation, can abolish phospho-T7 signals from ICK (Fig. 3C) . To test if ICK phosphorylates GSK3b-T7 in vivo, we employed both overexpression and knock-down approaches. Co-expression of HA-GSK3b with GST-ICK wild-type (WT), as compared with the kinase-dead (KD) mutant of ICK, in HEK293T cells resulted in a significant increase in the phospho-T7 signals which was completely abolished by the T7A mutation (Fig. 3D) . RIE-Ras 12V cells (H-Ras 12V oncogene transformed rat intestinal epithelial cells) displaying abundant phospho-GSK3b T7 signals were treated with validated ICK-specific lentiviral shRNA [28, 33] . Phospho-T7 signals were clearly down-regulated as a result of reduced ICK expression (Fig. 3E) . We conclude from these results that ICK is an upstream kinase for GSK3b Thr-7 both in vitro and in vivo.
Thr-8 phosphorylation partially inhibits GSK3b; but Thr-7 phosphorylation increases GSK3b activity and blocks phospho-S9-dependent inhibition of GSK3b
Structure of GSK3b suggests an intramolecular inhibitory mechanism in which the phosphorylated N-terminus of GSK3b acts as a competitive pseudosubstrate, occupying the positively charged binding pocket for the primed substrates [23] [24] [25] [26] . Given the proximity of Thr-7 and Thr-8 to Ser-9 on the N-terminus of GSK3b, we postulated that phospho-T7 or phospho-T8 may play a similar autoinhibitory role as phospho-S9 in the regulation of GSK3b activity toward its primed substrates. To test this hypothesis, we examined whether phospho-T7 or phosphor-T8 can substitute for phospho-S9 to inhibit GSK3b activity in vitro using the classic phosphopeptide inhibition assay. In consistent with previous reports [24, 25] , phospho-S9 peptides derived from the N-terminus of GSK3b effectively inhibited GSK3b activity as compared with unphosphorylated peptides (Fig. 4) . In comparison, phospho-T8 peptides only partially inhibited GSK3b activity, and surprisingly, phospho-T7 peptides exhibited a stimulatory rather than inhibitory effect on GSK3b activity (Fig. 4) . We also made an intriguing observation that phospho-T7/S9 peptides did not produce any significant inhibition of GSK3b (Fig. 4) . These results indicate that Thr-8 phosphorylation can partially trigger autoinhibition of GSK3b, whereas Thr-7 phosphorylation disrupts phospho-S9-dependent autoinhibition of GSK3b.
Discussion
Our findings here provided new insights into the phosphorylation-dependent autoregulation mechanism of GSK3b. It has been well-established that in response to insulin stimulation, AKT inhibits GSK3b activity via phosphorylation of Ser-9 [11] . Based on structural and biochemical evidence, the current model predicts that the phosphorylated N-terminal segment of GSK3b forms a loop long enough to bring phosphorylated Ser-9 in direct contact with the basic residues (Arg-96, Arg-180, and Lys-205) in the substrate binding grove, thus blocking access of the substrate to the substrate binding cleft (Fig. 5A ) [23] [24] [25] [26] . Given the proximity of Thr-7 and Thr-8 to Ser-9, it is conceivable that phosphorylated Thr-7 and Thr-8 residues may also participate in interactions with basic residues R96/R180/K205 in the substrate binding pocket to block substrate access to the active catalytic sites. However, our data underscores the selectivity of phospho-S9 and to a lesser extent of phospho-T8 in mediating the autoinhibitory effect of GSK3b (Fig. 5A, C) . We also made a novel observation that Thr-7 phosphorylation exerts a stimulatory rather than inhibitory In contrast, Thr-7 phosphorylation enhances GSK3b activity and blocks phospho-S9-mediated inhibition of GSK3b. GSK3b Nterminal peptides that are either unphosphorylated (CTL) or Ser-9 phosphorylated (pS9) or Thr-7 phosphorylated (pT7) or Thr-8 phosphorylated (pT8) or Thr-7/Ser-9 double-phosphorylated (pT7/S9) were incubated with active GSK3b kinase and primed phospho-GS peptide substrates for in vitro kinase assay. Radioactivities relative to the control were shown, mean AE SD, n = 3 independent experiments, *P < 0.01, **P < 0.001, NS, not significant. 
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Sub Fig. 5 . New insights into the autoinhibition model of GSK3b. (A) It has been well-established that insulin induces AKT phosphorylation of GSK3b-S9, which triggers conformational changes that allow the N-terminus of GSK3b to block the substrates from accessing its binding pocket, resulting in autoinhibition. (B) Shown in this study, the alanine mutation of highly conserved Thr-7 or Thr-8 residue within the AKT substrate consensus sequence R-P-R-T-T-S-F at the N-terminus of GSK3b impairs in vivo Ser-9 phosphorylation and GSK3b autoinhibition by insulin. (C) Shown in this study, Thr-8 phosphorylation triggers a partial inhibition of GSK3b as compared with Ser-9 phosphorylation. The upstream stimuli or the pathophysiological conditions that induce Thr-8 phosphorylation are unknown. (D) Shown in this study, intestinal cell kinase (ICK) specifically phosphorylates GSK3b-T7. Thr-7 phosphorylation blocks phospho-S9-mediated inhibition of GSK3b. The mechanisms underlying ICK activation and the crosstalk between pT7-pS9 in the regulation of GSK3b activity in vivo are unknown. effect on GSK3b, and phospho-Thr7 can prevent phospho-Ser9-induced autoinhibition of GSK3b (Fig. 5D ). This surprising result is indeed consistent with the prediction from a crystal structure of GSK3 that the packing of Thr-7 in the inhibitory peptide against Phe-67 in the glycine-rich loop of the N-terminal lobe (aa 62-70) is important for stabilizing a catalytically competent conformation [26] . A possible explanation for the stimulatory effect of phospho-T7 is that by forming electrostatic interactions and hydrogen bonds with Phe-67 and Phe-93, the phosphate group on phosphorylated Thr-7 further stabilizes the active conformation of GSK3b, and meanwhile alters the conformation of the binding interface between phospho-S9 and basic residues R96/R180/K205 in the substrate binding pocket, thus unblocking substrate access to the catalytic site. This intriguing hypothesis warrants further investigation.
Our data here demonstrated that although Thr-7 and Thr-8 residues are not strigently required for AKT phosphorylation of Ser-9 in vitro, they are essential for basal and insulin-stimulated Ser-9 phosphorylation in vivo and phospho-S9 induced GSK3b autoinhibition (Fig. 5B ). One possible explanation for different in vitro and in vivo results is that the in vitro system using only purified AKT and GSK3b proteins cannot recapitulate the complexity of multiprotein interactions that may be involved in AKT phosphorylation of GSK3b-S9 in vivo. We postulate that the alanine mutation at Thr-7 or Thr-8 disrupts hydrogen bonds that are critical for the formation of an optimal interface between AKT and GSK3b N-terminus, and thus hinders AKT phosphorylation of Ser-9 and GSK3b inactivation. Another possible explanation for the effect of T7A or T8A mutation on Ser-9 phosphorylation is through enhanced phosphatase reaction and turnover rate of phospho-S9. Our data from Calyculin inhibition experiment provided a strong argument against phosphatases as the main contributor to the observed effect of T7A or T8A mutation on Ser-9 phosphorylation. However, due to the nonquantitative nature of the experiment, we cannot conclude that the turover rate of phospho-S9 is unaffected by Thr-7/Thr-8 mutation.
We hereby provided compelling evidence that ICK is an upstream kinase for GSK3b Thr-7. In cells, overexpression of ICK led to a concurrent increase in GSK3b Thr-7 and Ser-9 phosphorylation, and conversely downregulation of ICK resulted in a similar decrease in both GSK3b phospho-Thr7 and phospho-Ser9 signals (Fig. S2) . These results raised the hypothesis that prephosphorylation of Thr-7 by ICK may promote Ser-9 phosphorylation. Many significant questions remain to be addressed. For example, does prephosphorylation with ICK enhance the ability of GSK-3b to act as an AKT substrate? Furthermore, is the ability of ICK to promote Ser-9 phosphorylation in cells dependent on Thr-7 or independent of potential regulation of AKT? In the structure of AKT complexed with GSK3b [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] peptide, GSK3b Thr-7 is predicted to form a hydrogen bond with AKT Glu-279 [27] . Thus, it is possible that Thr-7 phosphorylation may promote favorable conformational changes in the binding interface between GSK3b and AKT that facilitate Ser-9 phosphorylation by AKT. The exploration of the mechanisms underlying pThr7-pSer9 crosstalk is of great significance and merits further experimentation.
In our current model for GSK3b autoinhibition (Fig. 5) , a significant question that remains to be addressed is that under what physiological stimuli/conditions Thr-7 and Thr-8 are phosphorylated in vivo. A post-translational modification scan of critical signaling proteins by immunoaffinity enrichment coupled with mass spectrometry revealed three phospho-residues (Thr-7, Thr-8, and Ser-9) in the N-terminus of GSK3b, R-P-R-T7-T8-S9-F-A-E-S [36] . While phospho-Ser-9 site has been confirmed by site-specific methods, phospho-Thr-7/Thr-8 sites were assigned using only proteomic discovery-mode mass spectrometry, as summarized in PhosphoSitePlus Ò (www.phos phosite.org, powered by Cell Signaling Technology, Inc.). Our mass spectrometry data suggest that unlike Ser-9, both Thr-7 and Thr-8 are candidate phosphosites of very low stoichiometry under insulin stimulation (Sherman N.E. and Fu Z., unpublished data). This is consistent with prior observations from us and others that unlike MAP kinases, ICK is not catalytically activated by serum or growth factors, such as insulin and EGF [28, 29] . Another possible explanation is that phospho-T7/T8 sites undergo much faster turnovers than phospho-S9 site after insulin stimulation. Elevated expression of ICK and its upstream activating kinase CCRK/CDK20 (cell cycle related kinase/cyclin-dependent kinase 20) has been reported in various types of cancers [34, [37] [38] [39] . Whether Thr-7 phosphorylation is significantly up-regulated in cancer and contributes to tumor development and progression by promoting GSK3b activity is an intriguing question and currently under investigation.
In conclusion, within the AKT substrate consensus motif RPRT 7 T 8 S 9 F in the highly conserved N-terminus of GSK3b, Thr-7 and Thr-8 are essential for insulin-stimulated Ser-9 phosphorylation in vivo and GSK3b autoinhibition. Intestinal cell kinase (ICK) can specifically phosphorylate GSK3b Thr-7 in vitro and in vivo. While Thr-8 phosphorylation can only partially mimic Ser-9 phosphorylation in terms of autoinhibition of GSK3b on primed substrates, Thr-7 phosphorylation increases rather than reduces GSK3b activity and blocks phospho-S9-mediated autoinhibition of GSK3b. These new findings advanced the current model of GSK3b regulation by uncovering novel signaling inputs that are critical for GSK3b autoinhibition.
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